A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C

Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54(2):396-405.

Publication Type:

Journal Article

Authors:

Dienstag, J.L.; Ghany, M.G.; Morgan, T.R.; A M Di Bisceglie; Bonkovsky, H.L.; Kim, H.Y.; Seeff, L.B.; Szabo, G.; Wright, E.C.; R K Sterling; G.T. Everson; Lindsay, K.L.; Lee, W.M.; Lok, A.S.; Morishima, C.; Stoddard, A.M.; Everhart, J.E.; HALT-C trial group

Source:

Hepatology, Volume 54, Issue 2, p.396-405 (2011)

Keywords:

Antiviral Agents, Boston, Carcinoma, complications, Death, Disease, Disease Progression, drug therapy, Female, Fibrosis, hepatitis, Hepatitis C, Hepatitis C,Chronic, Humans, Incidence, interferon, Interferon Alfa-2a, Interferon-alpha, Liver, Liver Transplantation, Male, Massachusetts, Medicine, Middle Aged, pathology, Patients, peginterferon, Platelet Count, Polyethylene Glycols, Prospective Studies, Proteins, Recombinant Proteins, Research, Research Support, Ribavirin, therapeutic use, therapy, transplantation, treatment, Treatment Outcome

Notes:

PMC3144992

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/21520194

Export Citation:

RIS Format

Top